Chemistry:Ilomastat

From HandWiki
Revision as of 05:38, 6 May 2022 by imported>OrgMain (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
GM6001
Ilomastat.svg
Names
Preferred IUPAC name
(3R)-N1-Hydroxy-N4-{(1S)-1-[(1H-indol-3-yl)methyl]-2-(methylamino)-2-oxoethyl}-3-(2-methylpropyl)butanediamide
Other names
Galardin, GM6001
Identifiers
3D model (JSmol)
Abbreviations GM6
ChEBI
ChemSpider
DrugBank
MeSH GM6001
UNII
Properties
C20H28N4O4
Molar mass 388.468 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Ilomastat (INN),[1] (codenamed GM6001, proprietary name Galardin®) is a broad-spectrum matrix metalloproteinase inhibitor.[2][3][4]

This chemotherapy agent is considered to have application in skincare products for its antiaging properties.

Ilomastat is a member of the hydroxamic acid class of reversible metallopeptidase inhibitors. The anionic state of the hydroxamic acid group forms a bidentate complex with the active site zinc.[5]

Examples of enzymes that ilomastat inhibit include rabbit MMP9,[6] thermolysin,[2] peptide deformylase,[7] and anthrax lethal factor endopeptidase (LF) produced by the bacterium Bacillus anthracis.[8][9]

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 36". World Health Organization. p. 148. https://www.who.int/medicines/publications/druginformation/innlists/RL36.pdf. 
  2. 2.0 2.1 "Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids". Biochemistry 31 (31): 7152–4. August 1992. doi:10.1021/bi00146a017. PMID 1322694. 
  3. "Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases". Invest. Ophthalmol. Vis. Sci. 33 (12): 3325–31. November 1992. PMID 1385350. 
  4. "Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells". Exp. Cell Res. 290 (2): 437–46. November 2003. doi:10.1016/S0014-4827(03)00355-0. PMID 14568001. 
  5. "Small-molecule inhibitor J16.402: galardin". MEROPS - the Peptidase Database. Wellcome Trust Sanger Institute. 2010-09-07. http://merops.sanger.ac.uk/cgi-bin/smi_summary?mid=J16.402. 
  6. "An inhibitor of the matrix metalloproteinase synthesized by rabbit corneal epithelium". Invest Ophthalmol Vis Sci 32 (11): 2997–3001. 1991. PMID 1655675. 
  7. "Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium". J. Biol. Chem. 281 (24): 16691–9. June 2006. doi:10.1074/jbc.M513648200. PMID 16565079. 
  8. "Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells". Infect. Immun. 73 (11): 7548–57. November 2005. doi:10.1128/IAI.73.11.7548-7557.2005. PMID 16239558. 
  9. PDB: 1PWU​; "The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor". Nat. Struct. Mol. Biol. 11 (1): 60–6. January 2004. doi:10.1038/nsmb708. PMID 14718924.